[{"id":"10adfe7c-1a6c-43eb-9d18-a1d7306c999a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04166383","created_at":"2021-01-18T20:19:48.675Z","updated_at":"2024-07-02T16:35:29.876Z","phase":"Phase 2","brief_title":"VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT04166383","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ofranergene obadenovec (VB-111)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 08/09/2020","start_date":" 08/09/2020","primary_txt":" Primary completion: 04/12/2022","primary_completion_date":" 04/12/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-11-08"}]